CERUS CORPORATION (NASDAQ:CERS) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition

On January8, 2018, Cerus Corporation (the “Company”) announced its preliminary product revenue results for the fourth quarter and fiscal year ended December31, 2017. A copy of the Company’s press release, entitled “Cerus Corporation Announces Preliminary Product Revenue Results for Fourth Quarter and Full Year 2017,” is furnished to Item 2.02 as Exhibit99.1 hereto.

The information in this report, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such filing.

The following exhibit is furnished with this report:

2

CERUS CORP Exhibit
EX-99.1 2 d521973dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   Cerus Corporation Announces Preliminary Product Revenue Results for Fourth Quarter and Full Year 2017 Record preliminary product revenue reported along with expected strong 2018 growth CONCORD,…
To view the full exhibit click here

About CERUS CORPORATION (NASDAQ:CERS)

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company’s INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.